Investigating how modified RNA affects Alzheimer's disease
The role of N6-methyladenosine modified RNA in Alzheimer's disease
['FUNDING_R01'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-10994140
This study is looking at how a specific type of RNA modification might affect the buildup of tau protein in Alzheimer's disease, with the hope of finding new ways to help treat or slow down the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10994140 on ClinicalTrials.gov |
What this research studies
This research explores the role of N6-methyladenosine (m6A) modified RNA in the development and progression of Alzheimer's disease. It focuses on how the accumulation of oligomeric tau protein interacts with m6A and its associated proteins, which may contribute to neurodegeneration. By analyzing these interactions, the research aims to uncover new mechanisms behind Alzheimer's pathology and identify potential therapeutic targets. The study utilizes advanced models to assess how manipulating m6A levels can influence tau pathology and disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those at high risk due to genetic factors.
Not a fit: Patients with non-neurodegenerative conditions or those without any risk factors for Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting RNA modifications for neurodegenerative diseases, indicating potential for success in this novel approach.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOLOZIN, BENJAMIN L — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: WOLOZIN, BENJAMIN L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.